Inventiva S.A. is a clinical-stage biopharmaceutical company developing oral small molecule therapies for metabolic and fibrotic diseases. The company's lead program, Lanifibranor, is a pan-peroxisome proliferator-activated receptor agonist currently in Phase 3 clinical testing (NATiV3 trial) for metabolic dysfunction-associated steatohepatitis (MASH) in adult patients. The company also maintains development programs for Odiparcil, targeting mucopolysaccharidoses, and a pre-clinical program focused on TGF-β inhibition for idiopathic pulmonary fibrosis.
As a clinical-stage entity, Inventiva does not generate revenue from approved products. The company operates with a workforce of 84 full-time employees and is headquartered in Daix, France. The company was incorporated in 2011 and maintains its primary operations in France while conducting international clinical research. Inventiva is listed on Nasdaq, providing access to capital markets to fund ongoing development activities.
No 10-K filings found.